Polyelectrolyte microcapsules (PMC) based on polyallylamine and polystyrene sulfonate are utilized in various fields of human activity, including medicine, textiles, and the food industry, among others. However, characteristics such as microcapsule size, shell thickness, and pore size are not sufficiently studied and systematized, even though they determine the possibility of using microcapsules in applied tasks. The aim of this review is to identify general patterns and gaps in the study of the morphology of polyelectrolyte microcapsules obtained by the alternate adsorption of polystyrene sulfonate and polyallylamine on different solid cores. First and foremost, it was found that the morphological change in polyelectrolyte microcapsules formed on different cores exhibits a significant difference in response to varying stimuli. Factors such as ionic strength, the acidity of the medium, and temperature have different effects on the size of the microcapsules, the thickness of their shells, and the number and size of their pores. At present, the morphology of the microcapsules formed on the melamine formaldehyde core has been most studied, while the morphology of microcapsules formed on other types of cores is scarcely studied. In addition, modern methods of nanoscale system analysis will allow for an objective assessment of PMC characteristics and provide a fresh perspective on the subject of research.

More than half of the global population is unable to consume dairy products due to lactose intolerance (hypolactasia). Current enzyme replacement therapy methods are insufficiently effective as a therapeutic approach to treating lactose intolerance. The encapsulation of β-galactosidase in polyelectrolyte microcapsules by using the layer-by-layer method could be a possible solution to this problem. In this study, adsorption and co-precipitation methods were employed for encapsulating β-galactosidase in polyelectrolyte microcapsules composed of (polyallylamine /polystyrene sulphonate)₃. As a result, the co-precipitation method was chosen for β-galactosidase encapsulation. The adsorption method permits to encapsulate six times less enzyme compared with the co-precipitation method; the β-galactosidase encapsulated via the co-precipitation method released no more than 20% of the initially encapsulated enzyme in pH 2 or 1 M NaCl solutions. In contrast, when using the sorption method, about 100% of the initially encapsulated enzyme was released from the microcapsules under the conditions described above. The co-precipitation method effectively prevents the complete loss of enzyme activity after 2 h of incubation in a solution with pH 2 while also alleviating the adverse effects of ionic strength. Consequently, the encapsulated form of β-galactosidase shows promise as a potential therapeutic agent for enzyme replacement therapy in the treatment of hypolactasia.

The encapsulation of hydrophobic substances remains a significant challenge due to limitations such as low loading efficiency, leakage, and poor distribution within microcapsules. This study introduces a novel strategy utilizing colloidosomes assembled from polyelectrolyte microcapsules (PMCs). PMCs were fabricated via layer-by-layer (LbL) assembly on manganese carbonate (MnCO₃) or calcium carbonate (CaCO₃) cores, followed by core dissolution. A solvent gradient replacement method was employed to substitute the internal aqueous phase of PMCs with kerosene, enabling the formation of colloidosomes through self-assembly upon resuspension in water. Comparative analysis revealed that MnCO₃-based PMCs with smaller diameters (2.5–3 µm vs. 4.5–5.5 µm for CaCO₃) exhibited 3.5-fold greater stability, attributed to enhanced inter-capsule interactions via electrostatic and hydrophobic forces. Confocal microscopy confirmed the structural integrity of colloidosomes, featuring a liquid kerosene core encapsulated within a PMC shell. Temporal stability studies indicated structural degradation within 30 min, though 5% of colloidosomes retained integrity post-water evaporation. PMC-based colloidosomes exhibit significant application potential due to their integration of colloidosome functionality with PMC-derived structural features—semi-permeability, tunable shell thickness/composition, and stimuli-responsive behavior—enabling their adaptability to diverse technological and biomedical contexts. This innovation holds promise for applications in drug delivery, agrochemicals, and environmental technologies, where controlled release and stability are critical. The findings highlight the role of core material selection and solvent engineering in optimizing colloidosome performance, paving the way for advanced encapsulation systems.

Oral enzyme replacement therapy for lactase deficiency is limited by the rapid degradation of free β-galactosidase in the gastrointestinal tract. To overcome this, β-galactosidase was encapsulated into polyelectrolyte microcapsules (PMCs) via layer-by-layer assembly using MnCO₃ sacrificial templates, with CaCO₃-based PMCs as a reference. MnCO₃-PMCs achieved 99.4% encapsulation efficiency and retained 85.8% of initial activity, significantly outperforming CaCO₃-PMCs (86.0% and 29.7%). Under simulated gastric conditions (pH 2.0, pepsin), the free enzyme and CaCO₃-PMCs were completely inactivated, whereas MnCO3-PMCs preserved ~86% activity. In simulated intestinal fluid, MnCO₃-PMCs exhibited a 4.3-fold activity increase within the first hour and maintained a 2.5-fold enhancement after 70 h, while the free enzyme progressively inactivated. Furthermore, MnCO₃-PMCs demonstrated superior storage stability, retaining 64% of initial activity after 90 days at 4 °C, compared with 25% for CaCO₃-PMCs. Although immobilization increased the Michaelis constant, the shift was smaller for MnCO₃-PMCs (8.9-fold) than for CaCO₃-PMCs (15.2-fold). In conclusion, MnCO₃-templated PMCs effectively protect β-galactosidase from gastrointestinal degradation, sustain prolonged catalytic activity, and offer excellent storage stability, highlighting their strong potential for improving oral enzyme replacement therapy in lactose intolerance.